Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Obstetrics and Gynecology›Condition·Updated Jun 24, 2026·v1

Cervical Cancer v2 Surveillance and Follow-up

Cervical cancer surveillance is a structured, risk-adapted program that concentrates clinical intensity in the first 24 months — when 70–80% of recurrences emerge — and progressively de-escalates to annual visits after year 5. The backbone is symptom-focused history, physical examination with bimanual and rectovaginal assessment, and cervical/vaginal cytology ± HPV testing when the cervix or vagina is preserved. Cross-sectional imaging (CT, MRI, PET/CT) is reserved for symptom- or biomarker-triggered evaluation; routine scheduled imaging is not recommended in asymptomatic patients because of false positives, radiation exposure, and the harm of identifying incurable metastatic disease. Serum SCC-Ag and emerging HPV circulating tumor DNA provide lead times of 1–10 months over clinical detection, with HPV ctDNA offering the longest currently achievable window in HPV-associated disease. After the high-risk recurrence period closes, surveillance pivots to survivorship: late radiation toxicity management (favoring IMRT and adaptive brachytherapy per PARCER and EMBRACE-I), sexual health, psychosocial support, smoking cessation via the MAPS protocol, premature ovarian failure management, and family HPV prevention. Patient education on red-flag symptoms and a structured survivorship care plan convert a scheduled appointment into a long-term partnership.

High Evidence156 references·2,075 words·9 min read·v1
cervical cancersurveillanceoncology follow-upgynecologic oncologysurvivorshipHPV ctDNANCCN guidelineslate radiation toxicitysexual healthpsychosocial oncology

Quick Reference

RxDrug of choiceN/A — surveillance is non-pharmacologic; [[bevacizumab]] 15 mg/kg, platinum-based chemotherapy, and immune checkpoint inhibitors are reserved for confirmed recurrent/metastatic disease on the dedicated systemic-therapy page.
AltAlternativesN/A — no maintenance or prophylactic systemic agent is standard in surveillance; HPV therapeutic vaccination is investigational.
⊘AvoidRoutine intensive cross-sectional imaging (CT, MRI, PET/CT) in asymptomatic low-risk patients; reflex treatment change on biomarker elevation without tissue confirmation; estrogen-containing contraception in hormone-sensitive cervical adenocarcinoma variants.
DxTest of choiceSymptom-directed PET/CT (pooled sensitivity ~88% for lesions >1 cm) for suspected recurrence; cervical/vaginal [[cervical cytology|cytology]] ± [[HPV testing]] when the cervix or vagina is preserved; serum [[squamous cell carcinoma antigen|SCC-Ag]] for squamous histology (threshold 2 ng/mL or doubling titer); [[HPV circulating tumor DNA|HPV ctDNA]] as emerging lead-time biomarker.
ScKey scoreN/A — surveillance is risk-adapted by FIGO stage, treatment modality, nodal status, and time from treatment completion, not a single numeric score; FIGO 2018 staging and Sedlis/Peters adjuvant criteria govern preceding treatment decisions.
→When to referAny suspected recurrence → gynecologic oncology multidisciplinary team; severe late radiation toxicity (fistula, refractory fibrosis) → specialised late-effects or reconstructive clinic; persistent sexual dysfunction → specialised sexual-medicine clinic; clinically significant lymphedema → certified lymphedema therapist; psychosocial morbidity exceeding brief intervention capacity → psycho-oncology referral.
Risk-adapted surveillance concentrated in the first 24 months — symptoms lead, imaging confirms; survivorship care dominates after year 3.
Cervical cancer surveillance is a structured, risk-adapted program — not routine scanning. Roughly 70–80% of recurrences emerge within 24 months of definitive treatment, and most are first signalled by patient-reported symptoms, not scheduled imaging. The NCCN schedule front-loads clinical visits every 3–6 months in years 1–2, then de-escalates to annual visits after year 5, with cross-sectional imaging reserved for symptom- or biomarker-triggered evaluation. Serum SCC-Ag and emerging HPV circulating tumor DNA (ctDNA) provide lead times of 1–10 months over clinical detection, with HPV ctDNA offering the longest currently achievable window. After recurrence is excluded, the surveillance focus pivots to late toxicity management, sexual health, psychosocial support, and family HPV prevention — the survivorship burden that dominates long-term care.

Overview and Recommendations

Background

  • •Cervical cancer remains the fourth most common malignancy in women globally, with 5-year recurrence rates of 25–40% after definitive therapy depending on FIGO stage, HPV status, and treatment modality — making structured post-treatment surveillance a critical pillar of oncologic care.
  • •Roughly 70–80% of recurrences become clinically apparent within the first 24 months of completing therapy, a temporal distribution demonstrated in systematic reviews of distant metastatic patterns and that drives the front-loaded visit cadence embedded in NCCN, ESMO, and SGO follow-up algorithms.
  • •The surveillance paradigm has shifted away from calendar-driven intensive imaging toward risk-adapted, symptom- and biomarker-triggered evaluation — minimising radiation exposure, false-positive findings, and identification of incurable metastatic disease that does not change management.
  • •Three detection modalities now compete for the earliest lead time: patient-reported symptoms (universal but nonspecific), serum (squamous histology only), and (median 7–10 months lead time, the longest currently achievable in HPV-associated disease).
  • •After the high-risk recurrence window closes (year 3–5), surveillance pivots from recurrence detection to survivorship care — addressing late radiation toxicity, sexual dysfunction, psychosocial morbidity, premature ovarian failure, and the measurable excess risk of subsequent primary neoplasms.
  • •Guideline alignment is broad on principles but nuanced on details: NCCN, ESMO, and SGO converge on symptom-directed imaging, physical examination, and cytology ± HPV testing as the backbone; they diverge on routine surveillance imaging intensity and on clinical integration of HPV ctDNA, which remains investigational pending CALLA survival readout.

Evaluation

  • •Stratify visit frequency by time from treatment completion: every 3–6 months in years 1–2, every 6–12 months in years 3–5, then annually from year 5 onward — this cadence mirrors the empirical distribution of recurrence risk.
  • •Elicit a focused history at every visit, specifically asking about new vaginal bleeding, malodorous discharge, pelvic or back pain, unilateral leg oedema, hemoptysis, and changes in bowel or bladder habit — these patterns flag the majority of recurrences caught between scheduled imaging, with a median symptom lead time of 2–3 months.
  • •Perform a full physical examination with bimanual and rectovaginal assessment plus visual inspection of the vulva, vagina, and cervix (or vaginal cuff if post-hysterectomy); add ± when the cervix or vagina is preserved, with co-testing achieving NPV >95% for recurrent CIN2+ after fertility-sparing surgery.
  • •Reserve cross-sectional imaging (CT, MRI, PET/CT) for symptom- or biomarker-triggered evaluation — routine scheduled imaging is not recommended in asymptomatic patients because of false positives and the harm of identifying incurable metastatic disease.
  • •Consider a single at 3–6 months after definitive to document metabolic response; pooled sensitivity reaches ~88% for lesions >1 cm and PET/CT is the workhorse for nodal and distant metastatic evaluation when relapse is suspected.
  • •Use pelvic with T2-weighted and DWI sequences to separate radiation fibrosis from local-regional relapse after , where CT is unreliable.
  • •Order serum at each visit for squamous histology; a doubling titer or absolute value >2 ng/mL warrants imaging — note that SCC-Ag is insensitive for adenocarcinoma and adenocarcinoma variants.
  • •Consider (ctHPV DNA) in HPV-associated disease where the assay is available — detectable in ~90% of HPV-driven tumors at baseline, with persistence at end-of-treatment independently predicting relapse in CALLA biomarker analysis and serial plasma monitoring identifying clinical relapse a median of 7–10 months before conventional surveillance.
  • •Assess status at every visit — persistent smoking doubles second primary cancer risk, worsens late toxicity, and is the most modifiable behavioral driver of survivorship outcome.
  • •Screen for sexual dysfunction, vaginal stenosis, dyspareunia, and loss of libido using direct, non-leading questions; radiation-induced injury is under-reported unless probed and persists beyond 24 months in a substantial proportion of survivors.
  • •Screen for depression, anxiety, financial strain, and — social support deficits and financial toxicity are principal drivers of depressive symptoms in this population per recent meta-analytic data.
  • •Assess reproductive and menopausal status — is common after combined surgery and pelvic radiation, with downstream effects on bone, cardiovascular, and sexual health that warrant baseline DEXA and hormone-status evaluation.

Management

  • •Initiate structured survivorship care at the first post-treatment visit — define the schedule, name the red-flag symptoms, hand the patient a written list, and document the plan in the survivorship care record.
  • •Escalate to PET/CT when a new symptom, abnormal exam, or rising biomarker (
    2 ng/mL or doubling titer) triggers suspicion; biopsy or tissue confirmation is required when feasible before initiating salvage therapy, since post-treatment fibrosis can mimic tumor on imaging.
  • •Refer back to gynecologic oncology for any suspected recurrence; local-regional salvage (pelvic exenteration, brachytherapy re-irradiation) and systemic therapy (platinum-based chemotherapy ± 15 mg/kg, immune checkpoint inhibitors) require multidisciplinary coordination.
  • •Manage late radiation toxicity proactively — the phase III trial showed postoperative lowered 3-year grade ≥2 late GI toxicity compared with , and provides contemporary benchmarks for vaginal, rectal, and urinary late effects after MRI-guided adaptive with chemoradiation.
  • •Address sexual health with vaginal dilator use, topical estrogen where tolerated, lubricants, and referral to specialised sexual-medicine clinics; vaginal stenosis, dyspareunia, and agglutination are emphasised in NCCN guidance as under-recognised drivers of suffering.
  • •Offer psychosocial interventions — five weekly sessions plus a one-month booster of psychosocial telephone counseling has demonstrated QOL and cytokine-trajectory benefits versus usual care in cervical cancer survivors enrolled 9–30 months from diagnosis.
  • •Treat tobacco dependence aggressively — the telephone-based Motivation And Problem Solving program roughly doubled sustained abstinence versus standard counseling at 12–18 months in cervical cancer survivors and is cost-saving in modelled analyses.
  • •Manage with early physiotherapy referral, compression garments, and manual lymphatic drainage; document limb circumference at baseline visits and refer to certified lymphedema therapists when clinical signs emerge.
  • •Counsel on contraception and pregnancy on an individualised basis per Society of Family Planning/SGO guidance — estrogen-containing methods are usually avoided in hormone-sensitive disease, but pregnancy is rarely contraindicated; copper IUD and barrier methods are preferred where hormonal contraindications exist.
  • •Monitor bone health after with DEXA scanning at baseline and perimenopausal transition; supplement calcium and vitamin D as indicated and consider bone-protective agents in high-risk patients.
  • •Vaccinate household contacts — recommend for daughters aged 9–14 before sexual debut per WHO guidance, advise siblings and mother on local cervical screening, and counsel male partners per local guideline.
  • •Develop a structured survivorship care plan that documents treatment received, surveillance schedule, late-toxicity surveillance triggers, healthy-behaviour goals, and family screening recommendations; transition to general women's preventive care at year 5+ with annual cytology ± HPV testing.
  • •Avoid routine intensive imaging in asymptomatic low-risk patients — radiation exposure, false positives, and identification of incurable metastatic disease cause net harm and erode quality of life.
  • •Avoid reflex treatment change on a positive biomarker alone — confirm with imaging and tissue diagnosis before initiating salvage therapy, since inflammatory and post-radiation effects elevate SCC-Ag transiently.
  • •Refer to specialised late-effects or multidisciplinary clinics for severe radiation fibrosis, vesicovaginal or rectovaginal fistula, or refractory sexual dysfunction; structured supportive-care nursing interventions grounded in supportive-care theory reduce unmet needs during postoperative chemoradiation.

Board Review — High Yield

  • •70–80% within 24 months — roughly three-quarters of cervical cancer recurrences become clinically apparent in the first 2 years after definitive therapy, defining the high-yield surveillance window.
  • •First signal is usually the patient — patient-reported symptoms (vaginal bleeding, pelvic/back pain, unilateral leg oedema, hemoptysis, weight loss) catch most recurrences before scheduled imaging, with a median symptom lead time of 2–3 months.
  • •PET/CT pooled sensitivity ~88% — for lesions >1 cm in suspected recurrence; reserved for symptom- or marker-triggered evaluation, not routine surveillance.
  • •SCC-Ag threshold 2 ng/mL — a doubling titer or absolute value >2 ng/mL warrants imaging in squamous histology; SCC-Ag is insensitive for adenocarcinoma.
  • •HPV ctDNA lead time 7–10 months — detectable in ~90% of HPV-driven tumors at baseline; persistence at end-of-CRT independently predicts relapse in CALLA biomarker analysis.
  • •Routine imaging not recommended — NCCN does not endorse scheduled CT/MRI/PET in asymptomatic surveillance patients due to false positives and identification of incurable metastatic disease that does not change management.
  • •PARCER trial — postoperative [[intensity-modulated radiation therapy|IMRT]] reduced 3-year grade ≥2 late GI toxicity vs [[3D-CRT]] in women receiving adjuvant pelvic radiation.
  • •LACC trial — minimally invasive radical [[hysterectomy]] worsened oncologic outcomes without quality-of-life advantage over open surgery; [[SHAPE]] subsequently showed simple hysterectomy preserves sexual function (FSFI) for low-risk disease.
  • •MAPS smoking cessation — Motivation And Problem Solving telephone program roughly doubled sustained abstinence vs standard counseling at 12–18 months in cervical cancer survivors and is cost-saving in modelled analyses.
  • •Cervical cytology + HPV co-testing NPV >95% — for recurrent CIN2+ after fertility-sparing surgery when the cervix is preserved.

Deep Dive — Evidence Details

References

  1. [1]

    Reid E, Suneja G, Ambinder RF et al.. “AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787130 ↗

    L1GUIDELINECited in: Surveillance Schedule
  2. [2]

    Morice P, Scambia G, Abu-Rustum NR et al.. “Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE.” The Lancet. Oncology (2024). PMID: 39216500 ↗

    L1GUIDELINECited in: Surveillance Schedule
  3. [3]

    Chang HA, Armenian SH, Dellinger TH. “Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29439180 ↗

    L5SR_OBSCited in: Surveillance Schedule
  4. [4]

    Cetina L, González-Enciso A, Cantú D et al.. “Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23609186 ↗

    L1RCTCited in: Surveillance Schedule
  5. [5]

    Kenter GG, Greggi S, Vergote I et al.. “Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37656948 ↗

    L1RCTCited in: Surveillance Schedule, Late Toxicity and Survivorship
  6. [6]

    Gupta S, Maheshwari A, Parab P et al.. “Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29432076 ↗

    L1RCTCited in: Surveillance Schedule
  7. [7]

    Wentzensen N, Egemen D, Clarke MA et al.. “Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus-Positive With Dual Stain and Human Papillomavirus Genotyping.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41701950 ↗

    L2COHORTCited in: Surveillance Schedule
  8. [8]

    Vidrine JI, Sutton SK, Wetter DW et al.. “Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36921237 ↗

    L1RCTCited in: Surveillance Schedule, Late Toxicity and Survivorship, Patient Counselling
  9. [9]

    Chopra S, Gupta S, Kannan S et al.. “Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34506246 ↗

    L1RCTCited in: Surveillance Schedule, Late Toxicity and Survivorship
  10. [10]

    Katsumata N, Hirai Y, Kamiura S et al.. “Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21345941 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  11. [11]

    Kalliala I, Athanasiou A, Veroniki AA et al.. “Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 31959338 ↗

    L2SR_OBSCited in: Surveillance Schedule
  12. [12]

    Monk BJ, Toita T, Wu X et al.. “Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039991 ↗

    L1RCTCited in: Surveillance Schedule, Detection of Recurrence
  13. [13]

    Mileshkin LR, Moore KN, Barnes EH et al.. “Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37080223 ↗

    L1RCTCited in: Surveillance Schedule, Detection of Recurrence
  14. [14]

    Oaknin A, Moore K, Meyer T et al.. “Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.” The Lancet. Oncology (2024). PMID: 38608691 ↗

    L2RCTCited in: Surveillance Schedule, Detection of Recurrence
  15. [15]

    Chu T, Meng Y, Wu P et al.. “The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry.” The Lancet. Oncology (2023). PMID: 37269846 ↗

    L3COHORTCited in: Surveillance Schedule
  16. [16]

    Monk BJ, Tewari KS, Dubot C et al.. “Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2023). PMID: 36878237 ↗

    L1RCTCited in: Surveillance Schedule, Late Toxicity and Survivorship
  17. [17]

    Plante M, Kwon JS, Ferguson S et al.. “Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.” The New England journal of medicine (2024). PMID: 38416430 ↗

    L1RCTCited in: Surveillance Schedule, Detection of Recurrence
  18. [18]

    Palefsky JM, Lee JY, Jay N et al.. “Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.” The New England journal of medicine (2022). PMID: 35704479 ↗

    L1RCTCited in: Surveillance Schedule
  19. [19]

    Chung HC, Ros W, Delord JP et al.. “Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30943124 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  20. [20]

    Frenel JS, Le Tourneau C, O'Neil B et al.. “Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29095678 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  21. [21]

    O'Malley DM, Neffa M, Monk BJ et al.. “Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34932394 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule, Detection of Recurrence
  22. [22]

    Cho WK, Park W, Kim SW et al.. “Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38662364 ↗

    L2RCTCited in: Surveillance Schedule
  23. [23]

    Pötter R, Tanderup K, Schmid MP et al.. “MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.” The Lancet. Oncology (2021). PMID: 33794207 ↗

    L2TRIAL_NONRANDOMCited in: Surveillance Schedule, Late Toxicity and Survivorship
  24. [24]

    Coleman RL, Lorusso D, Gennigens C et al.. “Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.” The Lancet. Oncology (2021). PMID: 33845034 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule, Detection of Recurrence
  25. [25]

    Gao X, Xu N, Li Z et al.. “Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.” The Lancet. Oncology (2023). PMID: 37797632 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  26. [26]

    Li K, Chen J, Hu Y et al.. “Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 38048802 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  27. [27]

    Rombouts AJM, Hugen N, van Beek JJP et al.. “Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis.” Cancer treatment reviews (2018). PMID: 29957373 ↗

    L2SR_OBSCited in: Surveillance Schedule
  28. [28]

    Arbyn M, Simon M, de Sanjosé S et al.. “Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.” The Lancet. Oncology (2022). PMID: 35709810 ↗

    L1SR_OBSCited in: Surveillance Schedule
  29. [29]

    Mayadev JS, Enserro D, Lin YG et al.. “Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.” JAMA oncology (2020). PMID: 31774464 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule, Detection of Recurrence
  30. [30]

    Han K, Fyles A, Shek T et al.. “A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36037303 ↗

    L1RCTCited in: Surveillance Schedule
  31. [31]

    de la Rochefordiere A, Kamal M, Floquet A et al.. “PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25724520 ↗

    L1RCTCited in: Surveillance Schedule
  32. [32]

    Alimena S, Pachigolla SL, Feldman S et al.. “Race- and Age-Related Disparities in Cervical Cancer Mortality.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33789223 ↗

    L3OTHERCited in: Surveillance Schedule
  33. [33]

    Massad LS. “Developing guidelines for cervical cancer prevention in the face of diagnostic complexity.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24616540 ↗

    L1REVIEW_NARRATIVECited in: Surveillance Schedule
  34. [34]

    Rajendran JG, Greer BE. “Expanding role of positron emission tomography in cancer of the uterine cervix.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16687094 ↗

    L5REVIEW_NARRATIVECited in: Surveillance Schedule
  35. [35]

    Kimball KJ, Huh WK. “Cytology versus high-risk HPV testing for follow-up of HPV-positive women without CIN.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267062 ↗

    L5REVIEW_NARRATIVECited in: Surveillance Schedule
  36. [36]

    Papadopoulos KP, Johnson ML, Lockhart AC et al.. “First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796520 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  37. [37]

    Leo C, Horn LC, Rauscher C et al.. “Lack of apoptotic protease activating factor-1 expression and resistance to hypoxia-induced apoptosis in cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17317823 ↗

    L2TRIAL_NONRANDOMCited in: Surveillance Schedule
  38. [38]

    Kelly RJ, Draper D, Chen CC et al.. “A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21081657 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  39. [39]

    Kunos CA, Waggoner S, von Gruenigen V et al.. “Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20145183 ↗

    L4TRIAL_NONRANDOMCited in: Surveillance Schedule
  40. [40]

    Park JY, Kim DY, Kim JH et al.. “Management of occult invasive cervical cancer found after simple hysterectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19858083 ↗

    L3OTHERCited in: Surveillance Schedule, Detection of Recurrence
  41. [41]

    Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗

    L3OTHERCited in: Surveillance Schedule, Detection of Recurrence
  42. [42]

    Devi BC, Tang TS, Corbex M. “Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17434897 ↗

    L4OTHERCited in: Surveillance Schedule, Patient Counselling
  43. [43]

    Hwang JH, Kim H. “Comparison of clinical outcomes between early and delayed diagnosis of cervical cancer following abnormal Pap smear results: a population-based cohort study using National Health Insurance data in South Korea.” Journal of gynecologic oncology (2026). PMID: 42210769 ↗

    L3COHORTCited in: Surveillance Schedule
  44. [44]

    Ma J, Wang G, Wang W et al.. “Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.” Journal of gynecologic oncology (2026). PMID: 42210768 ↗

    L2COHORTCited in: Surveillance Schedule
  45. [45]

    Monk BJ, Colombo N, Tewari KS et al.. “First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37910822 ↗

    L1OTHERCited in: Surveillance Schedule
  46. [46]

    Cohen CM, Wentzensen N, Castle PE et al.. “Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36455190 ↗

    L2OTHERCited in: Surveillance Schedule
  47. [47]

    Schmid MP, Lindegaard JC, Mahantshetty U et al.. “Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36599120 ↗

    L2OTHERCited in: Surveillance Schedule
  48. [48]

    Han K, Zou J, Zhao Z et al.. “Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 37972346 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  49. [49]

    Çaltek NÇ, Yassa M, Bacaksız A et al.. “Preoperative hematological parameters do not predict lesion severity or recurrence in cervical intraepithelial neoplasia: a retrospective cohort study.” Discover oncology (2026). PMID: 42243395 ↗

    L3COHORTCited in: Surveillance Schedule
  50. [50]

    Lemoupa Makajio SH, Murtas M, Kenfack B et al.. “Interventions involving community health workers and their effect on cervical cancer screening uptake in sub-Saharan Africa: a systematic review.” BMC public health (2026). PMID: 42321728 ↗

    L2SR_OBSCited in: Surveillance Schedule, Patient Counselling
  51. [51]

    Yang Y, Yu M, Zeng M. “Distant metastasis in patients with cervical cancer: A systematic review and meta-analysis of incidence rates and common sites.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42171512 ↗

    L1SR_OBSCited in: Surveillance Schedule
  52. [52]

    Cabel L, Bonneau C, Bernard-Tessier A et al.. “HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.” ESMO open (2021). PMID: 34022731 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  53. [53]

    Bray F, Parkin DM. “Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.” The Lancet. Oncology (2022). PMID: 35550275 ↗

    L5REVIEW_NARRATIVECited in: Surveillance Schedule
  54. [54]

    Lei J, Ploner A, Elfström KM et al.. “HPV Vaccination and the Risk of Invasive Cervical Cancer.” The New England journal of medicine (2020). PMID: 32997908 ↗

    L2OTHERCited in: Surveillance Schedule
  55. [55]

    Tu H, Huang H, Li Y et al.. “Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.” The New England journal of medicine (2025). PMID: 41092328 ↗

    L1OTHERCited in: Surveillance Schedule, Detection of Recurrence
  56. [56]

    Melamed A, Margul DJ, Chen L et al.. “Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” The New England journal of medicine (2018). PMID: 30379613 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  57. [57]

    Goddard KAB, Feuer EJ, Mandelblatt JS et al.. “Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.” JAMA oncology (2025). PMID: 39636625 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  58. [58]

    Agustí N, Viveros-Carreño D, Wu CF et al.. “Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer.” JAMA oncology (2025). PMID: 40079948 ↗

    L2OTHERCited in: Surveillance Schedule
  59. [59]

    Taksler GB, Peterse EFP, Willems I et al.. “Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.” JAMA oncology (2021). PMID: 33914025 ↗

    L2OTHERCited in: Surveillance Schedule
  60. [60]

    Brunson A, Wun T, Abrahão R et al.. “Metastatic Recurrence Among Adolescents and Young Adults With Cancer.” JAMA oncology (2026). PMID: 41296369 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  61. [61]

    Clarke MA, Cheung LC, Castle PE et al.. “Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.” JAMA oncology (2019). PMID: 30325982 ↗

    L2OTHERCited in: Surveillance Schedule
  62. [62]

    Benard VB, Castle PE, Jenison SA et al.. “Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.” JAMA oncology (2017). PMID: 27685805 ↗

    L5OTHERCited in: Surveillance Schedule
  63. [63]

    Friedman CF, Ravichandran V, Miller K et al.. “Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37643132 ↗

    L5OTHERCited in: Surveillance Schedule
  64. [64]

    Seo A, Xiao W, Gjyshi O et al.. “Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680029 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  65. [65]

    Kang Z, Stevanović S, Hinrichs CS et al.. “Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899967 ↗

    L4OTHERCited in: Surveillance Schedule
  66. [66]

    Sivars L, Jylhä C, Crona Guterstam Y et al.. “Cell-Free Human Papillomavirus DNA Is a Sensitive Biomarker for Prognosis and for Early Detection of Relapse in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38669077 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  67. [67]

    Noordhuis MG, Eijsink JJ, Ten Hoor KA et al.. “Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19920104 ↗

    L2OTHERCited in: Surveillance Schedule
  68. [68]

    Jeannot E, Latouche A, Bonneau C et al.. “Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34210686 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  69. [69]

    Wei F, Du Y, Hu H et al.. “Development and internal-external validation of a nomogram for predicting postoperative 30-day malnutrition risk in cervical cancer patients: a retrospective cohort study.” American journal of cancer research (2026). PMID: 42163883 ↗

    L2COHORTCited in: Surveillance Schedule
  70. [70]

    Agha S. “Impact of behavioral insights-informed social media campaigns on HPV vaccination in Bangladesh.” PLOS global public health (2026). PMID: 42335084 ↗

    L2OTHERCited in: Surveillance Schedule
  71. [71]

    Cheung LC, Mao F, Rydzak G et al.. “Benefits and Harms of Immediate Versus Delayed Treatment of Cervical Intraepithelial Neoplasia Grade 2 : A Target Trial Emulation.” Annals of internal medicine (2026). PMID: 42330497 ↗

    L2OTHERCited in: Surveillance Schedule
  72. [72]

    Jerip AR, Noni V, Senian AA et al.. “Mismatch Between Vaccine Targets and Endemic HPV Genotypes in Sarawak, East Malaysia: Implications for Cervical Cancer Prevention.” Journal of medical virology (2026). PMID: 42324898 ↗

    L4OTHERCited in: Surveillance Schedule
  73. [73]

    Lencha B, Geda B, Ahmed K et al.. “Follow-up rescreening among women living with HIV who tested positive and treated for cervical pre-cancer lesions in South Ethiopia.” The oncologist (2026). PMID: 42316805 ↗

    L4OTHERCited in: Surveillance Schedule
  74. [74]

    Stalp JL, Schneider JA, Steinkasserer L et al.. “Comparing clinical decision-making between colposcopists and large language models in cervical dysplasia management: a pilot prospective multicenter study.” Archives of gynecology and obstetrics (2026). PMID: 42313159 ↗

    L4OTHERCited in: Surveillance Schedule
  75. [75]

    Saini V, Guo Z, Yu J et al.. “Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer.” Microbiology spectrum (2026). PMID: 42307270 ↗

    L2OTHERCited in: Surveillance Schedule, Detection of Recurrence
  76. [76]

    Abu-Rustum NR, Campos SM, Amarnath S et al.. “Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41825134 ↗

    L1GUIDELINECited in: Detection of Recurrence
  77. [77]

    Lorusso D, Colombo N, Dubot C et al.. “Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39393777 ↗

    L1RCTCited in: Detection of Recurrence
  78. [78]

    Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ et al.. “Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40500687 ↗

    L1RCTCited in: Detection of Recurrence
  79. [79]

    . “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗

    L1SR_OBSCited in: Detection of Recurrence
  80. [80]

    Kitagawa R, Katsumata N, Shibata T et al.. “Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732161 ↗

    L1RCTCited in: Detection of Recurrence, Late Toxicity and Survivorship
  81. [81]

    Xia L, Zhang K, Tang Y et al.. “Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40561369 ↗

    L2RCTCited in: Detection of Recurrence
  82. [82]

    Lorusso D, Ferrandina G, Pignata S et al.. “Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19605508 ↗

    L4TRIAL_NONRANDOMCited in: Detection of Recurrence
  83. [83]

    Thaker PH, Salani R, Brady WE et al.. “A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998970 ↗

    L4TRIAL_NONRANDOMCited in: Detection of Recurrence
  84. [84]

    Schuurman TN, Schaafsma M, To KH et al.. “Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.” The Lancet. Oncology (2023). PMID: 37952541 ↗

    L3COHORTCited in: Detection of Recurrence
  85. [85]

    Höckel M, Wolf B, Schmidt K et al.. “Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.” The Lancet. Oncology (2019). PMID: 31383547 ↗

    L2COHORTCited in: Detection of Recurrence
  86. [86]

    Vergote I, González-Martín A, Fujiwara K et al.. “Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.” The New England journal of medicine (2024). PMID: 38959480 ↗

    L1RCTCited in: Detection of Recurrence
  87. [87]

    Tewari KS, Monk BJ, Vergote I et al.. “Survival with Cemiplimab in Recurrent Cervical Cancer.” The New England journal of medicine (2022). PMID: 35139273 ↗

    L1RCTCited in: Detection of Recurrence, Late Toxicity and Survivorship
  88. [88]

    Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗

    L1RCTCited in: Detection of Recurrence, Late Toxicity and Survivorship
  89. [89]

    Ramirez PT, Frumovitz M, Pareja R et al.. “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.” The New England journal of medicine (2018). PMID: 30380365 ↗

    L1RCTCited in: Detection of Recurrence
  90. [90]

    Xu Q, Wang J, Sun Y et al.. “Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35192397 ↗

    L4TRIAL_NONRANDOMCited in: Detection of Recurrence
  91. [91]

    Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE et al.. “Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37651655 ↗

    L4TRIAL_NONRANDOMCited in: Detection of Recurrence
  92. [92]

    Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗

    L4TRIAL_NONRANDOMCited in: Detection of Recurrence
  93. [93]

    Birrer M, Li G, Yunokawa M et al.. “Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 39052242 ↗

    L4RCTCited in: Detection of Recurrence
  94. [94]

    Höckel M, Horn LC, Manthey N et al.. “Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis.” The Lancet. Oncology (2009). PMID: 19482513 ↗

    L2TRIAL_NONRANDOMCited in: Detection of Recurrence
  95. [95]

    Frumovitz M, Obermair A, Coleman RL et al.. “Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 32502445 ↗

    L1TRIAL_NONRANDOMCited in: Detection of Recurrence, Late Toxicity and Survivorship
  96. [96]

    Youn JW, Hur SY, Woo JW et al.. “Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 33271094 ↗

    L4TRIAL_NONRANDOMCited in: Detection of Recurrence
  97. [97]

    Penson RT, Huang HQ, Wenzel LB et al.. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).” The Lancet. Oncology (2015). PMID: 25638326 ↗

    L1TRIAL_NONRANDOMCited in: Detection of Recurrence, Late Toxicity and Survivorship
  98. [98]

    Pennington KP, Urban RR, Gray HJ. “Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659132 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  99. [99]

    Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  100. [100]

    Moore DH. “Chemotherapy for advanced, recurrent, and metastatic cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267059 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  101. [101]

    Hong DS, Concin N, Vergote I et al.. “Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796521 ↗

    L2TRIAL_NONRANDOMCited in: Detection of Recurrence
  102. [102]

    Oaknin A, Ghamande SA, Kasamatsu Y et al.. “Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38165683 ↗

    L2TRIAL_NONRANDOMCited in: Detection of Recurrence
  103. [103]

    Tewari KS. “Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026210 ↗

    L4CASE_REPORTCited in: Detection of Recurrence
  104. [104]

    Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗

    L1SR_OBSCited in: Detection of Recurrence
  105. [105]

    Dange HB, Kana IY, Suleiman HC et al.. “Cultural and traditional influences on cervical cancer screening uptake in Nigeria and other West African countries.” BMC public health (2026). PMID: 42015031 ↗

    L2SR_OBSCited in: Detection of Recurrence
  106. [106]

    Yokoi A, Machida H, Okazawa-Sakai M et al.. “Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 42012622 ↗

    L1SR_OBSCited in: Detection of Recurrence
  107. [107]

    Sankaranarayanan R, Boffetta P. “Research on cancer prevention, detection and management in low- and medium-income countries.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20231304 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  108. [108]

    Ngoma T. “World Health Organization cancer priorities in developing countries.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16801342 ↗

    L5OTHERCited in: Detection of Recurrence
  109. [109]

    Hao F, Cheng X, He J et al.. “A bibliometric analysis and visualization of trends in cervical cancer screening technologies based on dual-database analysis.” Frontiers in oncology (2026). PMID: 42294304 ↗

    L5SR_OBSCited in: Detection of Recurrence
  110. [110]

    Uppal S, Gehrig PA, Peng K et al.. “Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32031867 ↗

    L2REVIEW_NARRATIVECited in: Detection of Recurrence
  111. [111]

    Ogasawara A, Suzuki S, Oda K et al.. “Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).” Gynecologic oncology (2026). PMID: 42013608 ↗

    L2TRIAL_NONRANDOMCited in: Detection of Recurrence
  112. [112]

    Van Nieuwenhuysen E, Vergote I, Randall LM et al.. “Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.” Gynecologic oncology (2026). PMID: 42000372 ↗

    L2TRIAL_NONRANDOMCited in: Detection of Recurrence
  113. [113]

    Monk BJ, Enomoto T, Kast WM et al.. “Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.” Cancer treatment reviews (2022). PMID: 35413489 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  114. [114]

    Pectasides D, Kamposioras K, Papaxoinis G et al.. “Chemotherapy for recurrent cervical cancer.” Cancer treatment reviews (2008). PMID: 18657909 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  115. [115]

    Tolcher A, Hamilton E, Coleman RL. “The evolving landscape of antibody-drug conjugates in gynecologic cancers.” Cancer treatment reviews (2023). PMID: 37023499 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  116. [116]

    Mountzios G, Soultati A, Pectasides D et al.. “Developments in the systemic treatment of metastatic cervical cancer.” Cancer treatment reviews (2013). PMID: 22727690 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  117. [117]

    Gennigens C, Jerusalem G, Lapaille L et al.. “Recurrent or primary metastatic cervical cancer: current and future treatments.” ESMO open (2022). PMID: 36108558 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  118. [118]

    Elit L, Haruyama R, Gatti A et al.. “Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports.” ESMO open (2020). PMID: 33310778 ↗

    L5OTHERCited in: Detection of Recurrence
  119. [119]

    Lheureux S, Butler MO, Clarke B et al.. “Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.” JAMA oncology (2018). PMID: 29145543 ↗

    L2OTHERCited in: Detection of Recurrence
  120. [120]

    Tewari KS, Monk BJ. “New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25104084 ↗

    L5REVIEW_NARRATIVECited in: Detection of Recurrence
  121. [121]

    Miller KM, Friedman CF. “Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35947045 ↗

    L5OTHERCited in: Detection of Recurrence
  122. [122]

    Da Silva DM, Enserro DM, Mayadev JS et al.. “Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32816895 ↗

    L2OTHERCited in: Detection of Recurrence
  123. [123]

    Baudin L, Zanella L, Lebeau A et al.. “Nonmetastatic Para-aortic Lymph Node Remodeling as a Predictor of Outcome in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41779008 ↗

    L2OTHERCited in: Detection of Recurrence
  124. [124]

    He P, Wang Y, Xie N et al.. “Diagnostic Accuracy and Concordance of Self-Collected Cervical CDO1 and CELF4 Methylation Testing Compared With Physician Sampling for Endometrial Cancer Detection.” JCO precision oncology (2026). PMID: 42314091 ↗

    L2OTHERCited in: Detection of Recurrence
  125. [125]

    Challgua CH, Rodriguez DE, Goicolea I et al.. “Barriers and facilitators in access to cervical cancer secondary prevention in Cochabamba, Bolivia: a qualitative study of healthcare providers' perceptions.” BMC primary care (2026). PMID: 42298405 ↗

    L5OTHERCited in: Detection of Recurrence
  126. [126]

    Darahan H, Rodyna R, Germanovych M et al.. “Supporting primary health care led preventive screening through community-embedded health access points in Ukraine.” Frontiers in public health (2026). PMID: 42293662 ↗

    L4OTHERCited in: Detection of Recurrence
  127. [127]

    Ryu SY, Deng W, Albuquerque K et al.. “Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40947016 ↗

    L1RCTCited in: Late Toxicity and Survivorship
  128. [128]

    Ferguson SE, Brotto LA, Kwon J et al.. “Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 39353164 ↗

    L1RCTCited in: Late Toxicity and Survivorship
  129. [129]

    Wenzel L, Osann K, Hsieh S et al.. “Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25713429 ↗

    L1RCTCited in: Late Toxicity and Survivorship, Patient Counselling
  130. [130]

    Ramondetta L. “What is the appropriate approach to treating women with incurable cervical cancer?” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23486459 ↗

    L5REVIEW_NARRATIVECited in: Late Toxicity and Survivorship
  131. [131]

    Ryu SY, Nam BH, Kim MH et al.. “A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.” ESMO open (2026). PMID: 41812622 ↗

    L1RCTCited in: Late Toxicity and Survivorship
  132. [132]

    Sunguc C, Winter DL, Heymer EJ et al.. “Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study.” The Lancet. Oncology (2024). PMID: 38944050 ↗

    L3COHORTCited in: Late Toxicity and Survivorship
  133. [133]

    Bright CJ, Reulen RC, Winter DL et al.. “Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study.” The Lancet. Oncology (2019). PMID: 30797674 ↗

    L3COHORTCited in: Late Toxicity and Survivorship
  134. [134]

    Batur P, Brant A, McCourt C et al.. “Society of Family Planning Clinical Recommendation: Contraceptive considerations for individuals with cancer and cancer survivors part 3 - Skin, blood, gastrointestinal, liver, lung, central nervous system, and other cancers: Joint with the Society of Gynecologic Oncology.” Contraception (2025). PMID: 40328522 ↗

    L1GUIDELINECited in: Late Toxicity and Survivorship
  135. [135]

    Batur P, Brant A, McCourt C et al.. “Society of Family Planning Committee Statement: Contraceptive considerations for individuals with cancer and cancer survivors part 1 - Key considerations for clinical care Joint with the Society of Gynecologic Oncology.” Contraception (2025). PMID: 40210504 ↗

    L5GUIDELINECited in: Late Toxicity and Survivorship, Patient Counselling
  136. [136]

    Batur P, Brant A, McCourt C et al.. “Society of Family Planning Clinical Recommendation: Contraceptive considerations for individuals with cancer and cancer survivors part 2 - Breast, ovarian, uterine, and cervical cancer: Joint with the Society of Gynecologic Oncology.” Contraception (2025). PMID: 40190008 ↗

    L1GUIDELINECited in: Late Toxicity and Survivorship
  137. [137]

    Nelson EL, Wenzel LB, Osann K et al.. “Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18381952 ↗

    L1RCTCited in: Late Toxicity and Survivorship, Patient Counselling
  138. [138]

    George GC, Andersen C, Tang X et al.. “Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38996438 ↗

    L2OTHERCited in: Late Toxicity and Survivorship
  139. [139]

    Hathout L, Zhang Y, Lymberis S et al.. “A Systematic Review of Patient-Reported Outcomes on the Impact of Radiation Therapy on Sexual Health in Patients With Gynecologic Cancer.” International journal of radiation oncology, biology, physics (2026). PMID: 41720168 ↗

    L1SR_OBSCited in: Late Toxicity and Survivorship, Patient Counselling
  140. [140]

    Umemiya M, Kou K, Inayama Y et al.. “Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 41612081 ↗

    L1SR_OBSCited in: Late Toxicity and Survivorship
  141. [141]

    Wang R, Liu B, Wei SW et al.. “Meta-analysis of factors influencing depression in cervical cancer patients.” Frontiers in public health (2025). PMID: 41256286 ↗

    L2SR_OBSCited in: Late Toxicity and Survivorship
  142. [142]

    Chalif J, Morton M, Haight P et al.. “Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review.” American journal of obstetrics and gynecology (2026). PMID: 41072704 ↗

    L1SR_OBSCited in: Late Toxicity and Survivorship
  143. [143]

    Chona EZ, Gosse RA, Msengi EA et al.. “Life Experiences of Women Diagnosed With Cervical Cancer in Sub-Saharan Africa: A Systematic Review of Qualitative Studies.” Psycho-oncology (2025). PMID: 40930811 ↗

    L5SR_OBSCited in: Late Toxicity and Survivorship
  144. [144]

    Liu X, Vidrine DJ, Sutton SK et al.. “Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer.” JAMA network open (2026). PMID: 41817524 ↗

    L2RCTCited in: Late Toxicity and Survivorship
  145. [145]

    Vermaas EM, Wenzel HHB, van der Aa MA et al.. “Impact of COVID-19 on oncological outcomes during follow-up in gynaecological cancer: A nationwide retrospective cohort study.” Gynecologic oncology (2026). PMID: 41564614 ↗

    L3COHORTCited in: Late Toxicity and Survivorship
  146. [146]

    Pingault O, Moskal A, Bouvard C et al.. “Gynaecological follow-up of adolescent and young adult cancer survivors: a comparative cohort study.” BMJ open (2025). PMID: 41475832 ↗

    L3COHORTCited in: Late Toxicity and Survivorship
  147. [147]

    Chase DM, Huang HQ, Deng W et al.. “Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).” Gynecologic oncology (2025). PMID: 41056581 ↗

    L1RCTCited in: Late Toxicity and Survivorship
  148. [148]

    Duan S, Su Y, Niu Q et al.. “Construction and implementation of a nursing intervention program based on supportive care theory for cervical cancer patients receiving postoperative concurrent chemoradiotherapy.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 40935918 ↗

    L2RCTCited in: Late Toxicity and Survivorship
  149. [149]

    Jones KF, Osazuwa-Peters OL, Des Marais A et al.. “Substance Use Disorders Among US Adult Cancer Survivors.” JAMA oncology (2024). PMID: 38206609 ↗

    L2OTHERCited in: Late Toxicity and Survivorship
  150. [150]

    Marucci da Silva GF, Pilger TL, Candido Dos Reis FJ. “Incidence of urologic co-morbidities after abdominal radical hysterectomy: a systematic review of clinical trials.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41259843 ↗

    L1TRIAL_NONRANDOMCited in: Patient Counselling
  151. [151]

    Treasure ML, Nourbakhsh PS, Diaz Roldan K et al.. “Preventive Health Services in Reproductive-Aged Women with Diabetes Mellitus: A Scoping Review.” Journal of general internal medicine (2026). PMID: 41926034 ↗

    L5SR_OBSCited in: Patient Counselling
  152. [152]

    Huang WL, Lin IM, Huang WT et al.. “Effects of a telephone intervention on breast, cervical, and colorectal cancer screening: A meta-analysis.” Preventive medicine reports (2026). PMID: 41550473 ↗

    L1SR_OBSCited in: Patient Counselling
  153. [153]

    Mengistie BA, Yirsaw AN, Lakew G et al.. “Human papillomavirus vaccine uptake and its determinants among women in Africa: an umbrella review.” Frontiers in public health (2025). PMID: 40538696 ↗

    L2SR_OBSCited in: Patient Counselling
  154. [154]

    Maleki A, Ahadinezhad B, Alizadeh A et al.. “Barriers and facilitators of pap-smear test uptake in Asia: a systematic review.” BMC public health (2025). PMID: 40426094 ↗

    L2SR_OBSCited in: Patient Counselling
  155. [155]

    Sabatino SA, Coates RJ, Uhler RJ et al.. “Provider counseling about health behaviors among cancer survivors in the United States.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17513816 ↗

    L2OTHERCited in: Patient Counselling
  156. [156]

    Lai CH, Chang CJ, Huang HJ et al.. “Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17704412 ↗

    L4OTHERCited in: Patient Counselling

Revision History

All updates applied to this page

Loading revisions…